261 related articles for article (PubMed ID: 18216244)
1. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
Atanackovic D; Altorki NK; Cao Y; Ritter E; Ferrara CA; Ritter G; Hoffman EW; Bokemeyer C; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2008 Feb; 105(5):1650-5. PubMed ID: 18216244
[TBL] [Abstract][Full Text] [Related]
2. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
[TBL] [Abstract][Full Text] [Related]
3. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
[TBL] [Abstract][Full Text] [Related]
4. High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.
Saito T; Wada H; Yamasaki M; Miyata H; Nishikawa H; Sato E; Kageyama S; Shiku H; Mori M; Doki Y
Vaccine; 2014 Oct; 32(45):5901-7. PubMed ID: 25218300
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
[TBL] [Abstract][Full Text] [Related]
6. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer.
Pujol JL; Vansteenkiste JF; De Pas TM; Atanackovic D; Reck M; Thomeer M; Douillard JY; Fasola G; Potter V; Taylor P; Bosquée L; Scheubel R; Jarnjak S; Debois M; de Sousa Alves P; Louahed J; Brichard VG; Lehmann FF
J Thorac Oncol; 2015 Oct; 10(10):1458-67. PubMed ID: 26309191
[TBL] [Abstract][Full Text] [Related]
8. Induction of Humoral and Cellular Immune Responses in Mice by Multiepitope Vaccines Composing of Both T and B Lymphocyte Epitopes of MAGE-A3 which are Recombined into HBcAg.
Chen Q; Li W; Wang P; Shao H; Ding Y; Wang W; Cen D; Cai Y; Xue X; Zhang L; Zhu G
Protein Pept Lett; 2017; 24(10):947-954. PubMed ID: 28641561
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
[TBL] [Abstract][Full Text] [Related]
10. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.
Vantomme V; Dantinne C; Amrani N; Permanne P; Gheysen D; Bruck C; Stoter G; Britten CM; Keilholz U; Lamers CH; Marchand M; Delire M; Guéguen M
J Immunother; 2004; 27(2):124-35. PubMed ID: 14770084
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Russo V; Pilla L; Lunghi F; Crocchiolo R; Greco R; Ciceri F; Maggioni D; Fontana R; Mukenge S; Rivoltini L; Rigamonti G; Mercuri SR; Nicoletti R; Maschio AD; Gianolli L; Fazio F; Marchianò A; Florio AD; Maio M; Salomoni M; Gallo-Stampino C; Fiacco MD; Lambiase A; Coulie PG; Patuzzo R; Parmiani G; Traversari C; Bordignon C; Santinami M; Bregni M
Int J Cancer; 2013 Jun; 132(11):2557-66. PubMed ID: 23151995
[TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
[TBL] [Abstract][Full Text] [Related]
15. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
16. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
17. A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Chianese-Bullock KA; Mauldin IS; Smith KT; Deacon DH; Varhegyi NE; Donnelly SB; Reed CM; Scott K; Galeassi NV; Grosh WW
Cancer Immunol Immunother; 2016 Jan; 65(1):25-36. PubMed ID: 26581199
[TBL] [Abstract][Full Text] [Related]
18. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
19. MAGE A3 antigen-specific cancer immunotherapeutic.
Peled N; Oton AB; Hirsch FR; Bunn P
Immunotherapy; 2009 Jan; 1(1):19-25. PubMed ID: 20635969
[TBL] [Abstract][Full Text] [Related]
20. An In vivo study: Adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide.
Kızılbey K; Mansuroğlu B; Derman S; Mustafaeva Akdeste Z
Bioengineered; 2018 Jan; 9(1):134-143. PubMed ID: 28910565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]